Clinical trials: Abiraterone Acetate
Prostate Cancer
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.
- Trial name
- NCT01717053
- Testing
- Abiraterone acetate, Androgen deprivation, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Duke University
Castrate-resistant Prostate Cancer
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
There will be two parts to this clinical research study. The purpose of each part is: Phase 1: This part of the study will determine what dose of BEZ235 is safe to give with a standard dose of abiraterone acetate and prednisone…
- Trial name
- NCT01717898
- Testing
- BEZ235, Prednisone, Abiraterone acetate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Charles Ryan
Metastatic Castration-resistant Prostate Cancer
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed…
- Trial name
- NCT05457257
- Testing
- olaparib, enzalutamide, abiraterone acetate
- Where
- 35 sites in China
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Prostate Neoplasms
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have…
- Trial name
- NCT01715285
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 208 sites in Argentina, Australia and 31 more
- Volunteers
- 1,209 people
- Sponsor
- Janssen Research & Development, LLC
Castration-resistant Prostate Cancer
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer
This study is comparing the safety and effectiveness of abiraterone acetate alone, followed by the addition of prednisone (when the participant's disease worsens or the physician feels it would lessen symptoms of toxicity) versus…
- Trial name
- NCT02025010
- Testing
- abiraterone acetate
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Castration Resistant Prostate Cancer
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
The purpose of this study is to find out what effects, good and/or bad,an increased dose of Abiraterone Acetate in combination with prednisone has on patients and their prostate cancer.
- Trial name
- NCT01637402
- Testing
- Abiraterone Acetate, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Terence Friedlander, MD
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies selinexor in treating patients with prostate cancer that has spread to other parts of the body (metastatic), keeps growing even when the amount of testosterone in the body is reduced to very low levels…
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT02215161
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Prostatic Neoplasms
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
The purpose of this study is to evaluate the efficacy, based on prostate-specific antigen (PSA) progression, of abiraterone acetate in participants with metastatic (spread of cancer cells from one part of the body to another)…
- Trial name
- NCT02217566
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 4 sites in Brazil
- Volunteers
- 46 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
The purpose of this research study is to determine if the addition of dutasteride to a regimen with abiraterone acetate and prednisone will improve on therapy in patients with castrate-resistant prostate cancer and metastatic…
- Trial name
- NCT01393730
- Testing
- Abiraterone acetate, Dutasteride, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mary-Ellen Taplin, MD
Prostate Cancer
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
This research study is being offered to those patients who have received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable despite having received at…
- Trial name
- NCT03777982
- Testing
- Prednisone, Apalutamide, Abiraterone Acetate
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This randomized phase II trial studies abiraterone acetate and prednisone together with veliparib to see how well it works compared to abiraterone acetate and prednisone alone in treating patients with castration-resistant…
- Conditions
- Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT01576172
- Testing
- Abiraterone Acetate, Laboratory Biomarker Analysis, Prednisone
- Where
- 14 sites in United States
- Volunteers
- 159 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with…
- Trial name
- NCT02257736
- Testing
- Apalutamide, Abiraterone acetate, Prednisone
- Where
- 173 sites in United States, Argentina and 14 more
- Volunteers
- 982 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma
Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
This phase II trial studies how well docetaxel or abiraterone acetate work when combined with androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread to other parts of the…
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer
- Trial name
- ACADEMIC (NCT03827473)
- Testing
- Abiraterone Acetate, Antiandrogen Therapy, Docetaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Castration-Resistant Prostatic Cancer
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
- Trial name
- MAGNITUDE (NCT03748641)
- Testing
- Niraparib, Abiraterone Acetate, Prednisone
- Where
- 318 sites in United States, Argentina and 27 more
- Volunteers
- 765 people
- Sponsor
- Janssen Research & Development, LLC
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT03419234
- Testing
- Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel
- Where
- 672 sites in United States, Puerto Rico
- Volunteers
- 223 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Neoplasms, Prostate Cancer
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to establish the safety profile of oral (by mouth) abiraterone acetate and oral prednisone following short-term administration after standardized low-fat or high-fat meals to patients with metastatic…
- Trial name
- NCT01424930
- Testing
- Abiraterone, Prednisone
- Where
- 2 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Janssen-Ortho Inc., Canada
Prostate Cancer
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Primary Objectives: To determine the maximum tolerated dose, and dose limiting toxicities of cabazitaxel administered as a 1-hour infusion every 3 weeks in combination with oral daily abiraterone acetate and prednisone in…
- Trial name
- NCT01511536
- Testing
- Cabazitaxel XRP6258, Abiraterone acetate, Prednisone 5 mg
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 38 people
- Sponsor
- Sanofi
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well abiraterone acetate works in treating patients with hormone-resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic).
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- NCT01503229
- Testing
- Abiraterone Acetate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Metastatic Prostate Cancer
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
This study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to…
- Trial name
- NCT04262154
- Testing
- Atezolizumab, Abiraterone, Prednisone
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Adenocarcinoma, Prostate Cancer
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
This study is comparing the effectiveness of enzalutamide with or without abiraterone acetate for men with high-risk, localized prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer
- Trial name
- NCT02268175
- Testing
- Enzalutamide, Abiraterone Acetate, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Dana-Farber Cancer Institute